Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...

Imara Reports First Quarter 2020 Financial Results and Business Highlights Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...

Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders BOSTON, May 06, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...